[go: up one dir, main page]

CY1109944T1 - Παραγωγα ν-(αμινο-ετεροαρυλ)-1η-ινδολ-2-καρβοξαμιδιων, η παρασκευη τους και η εφαρμογη τους σε θεραπειες - Google Patents

Παραγωγα ν-(αμινο-ετεροαρυλ)-1η-ινδολ-2-καρβοξαμιδιων, η παρασκευη τους και η εφαρμογη τους σε θεραπειες

Info

Publication number
CY1109944T1
CY1109944T1 CY20101100268T CY101100268T CY1109944T1 CY 1109944 T1 CY1109944 T1 CY 1109944T1 CY 20101100268 T CY20101100268 T CY 20101100268T CY 101100268 T CY101100268 T CY 101100268T CY 1109944 T1 CY1109944 T1 CY 1109944T1
Authority
CY
Cyprus
Prior art keywords
application
heteroyrarl
indol
treatments
amino
Prior art date
Application number
CY20101100268T
Other languages
English (en)
Inventor
Laurent Dubois
Yannick Evanno
André Malanda
David Machnik
Catherine Gille
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of CY1109944T1 publication Critical patent/CY1109944T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η εφεύρεση αφορά σε ενώσεις του γενικού χημικού τύπου (I) στον οποίο το Z1, το Ζ2, το Ζ3, το Ζ4 αντιπροσωπεύουν ανεξάρτητα το ένα από το άλλο, ένα άτομο αζώτου ή μια ομάδα C(R6), τουλάχιστον ένα εξ' αυτών αντιστοιχεί σε ένα άτομο αζώτου και τουλάχιστον ένα εξ' αυτών αντιστοιχεί σε μια ομάδα C(R6)· το n ισούται με 0, 1, 2 ή 3 · το Υ είναι ενδεχομένως υποκατεστημένο αρυλ ή ετεροαρυλ · το Ζ αντιπροσωπεύει μια κυκλική αμίνη η οποία συνδέεται με το άτομο αζώτου του χημικού τύπου ∙ σε κατάσταση βάσης ή άλατος προσθήκης σε ένα οξύ, καθώς και σε κατάσταση υδρίτη ή διαλύτη. Επίσης αφορά στην διαδικασία παρασκευής τους και στην εφαρμογή τους σε θεραπείες.
CY20101100268T 2006-07-31 2010-03-22 Παραγωγα ν-(αμινο-ετεροαρυλ)-1η-ινδολ-2-καρβοξαμιδιων, η παρασκευη τους και η εφαρμογη τους σε θεραπειες CY1109944T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0606988A FR2904316B1 (fr) 2006-07-31 2006-07-31 Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
EP07823371A EP2049525B1 (fr) 2006-07-31 2007-07-30 Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
CY1109944T1 true CY1109944T1 (el) 2014-09-10

Family

ID=37806631

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100268T CY1109944T1 (el) 2006-07-31 2010-03-22 Παραγωγα ν-(αμινο-ετεροαρυλ)-1η-ινδολ-2-καρβοξαμιδιων, η παρασκευη τους και η εφαρμογη τους σε θεραπειες

Country Status (36)

Country Link
US (2) US7786104B2 (el)
EP (1) EP2049525B1 (el)
JP (1) JP5306201B2 (el)
KR (1) KR20090033885A (el)
CN (1) CN101511819B (el)
AR (1) AR062143A1 (el)
AT (1) ATE453637T1 (el)
AU (1) AU2007280326B2 (el)
BR (1) BRPI0715199A2 (el)
CA (1) CA2658799C (el)
CL (1) CL2007002169A1 (el)
CO (1) CO6150179A2 (el)
CY (1) CY1109944T1 (el)
DE (1) DE602007004119D1 (el)
DK (1) DK2049525T3 (el)
EA (1) EA017375B1 (el)
ES (1) ES2338610T3 (el)
FR (1) FR2904316B1 (el)
HR (1) HRP20100121T1 (el)
IL (1) IL196571A0 (el)
JO (1) JO2644B1 (el)
MA (1) MA30695B1 (el)
ME (1) ME00590A (el)
MX (1) MX2009001222A (el)
MY (1) MY145031A (el)
NO (1) NO20090952L (el)
NZ (1) NZ574345A (el)
PE (1) PE20080688A1 (el)
PL (1) PL2049525T3 (el)
PT (1) PT2049525E (el)
RS (1) RS51235B (el)
SI (1) SI2049525T1 (el)
TW (1) TW200813023A (el)
UY (1) UY30518A1 (el)
WO (1) WO2008015335A1 (el)
ZA (1) ZA200900505B (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
FR2926554B1 (fr) * 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926556B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
FR2926553B1 (fr) * 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
CA2756870A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted indolo-pyridinone compounds
KR101699822B1 (ko) 2011-12-21 2017-01-25 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
AR092269A1 (es) 2012-08-28 2015-04-08 Janssen R&D Ireland Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
SI2961732T1 (sl) 2013-02-28 2017-07-31 Janssen Sciences Ireland Uc Sulfamoil-arilamidi in njihova uporaba kot zdravila za zdravljenje hepatitisa B
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B
US10160743B2 (en) 2013-05-17 2018-12-25 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
SG10201805033XA (en) 2013-07-25 2018-07-30 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JP6452119B2 (ja) 2013-10-23 2019-01-16 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カルボキサミド誘導体およびb型肝炎の処置のための医薬品としてのその使用
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JP6553059B2 (ja) 2014-02-05 2019-07-31 ノヴィラ・セラピューティクス・インコーポレイテッド Hbv感染の治療のための併用療法
US11078193B2 (en) 2014-02-06 2021-08-03 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CA2980298A1 (en) 2015-03-19 2016-09-22 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN108430971A (zh) 2015-09-29 2018-08-21 诺维拉治疗公司 乙型肝炎抗病毒剂的晶体形式
BR112018071048A2 (pt) 2016-04-15 2019-05-07 Janssen Sciences Ireland Uc combinações e métodos que compreendem um inibidor da montagem de capsídeos
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
CU24560B1 (es) 2017-01-23 2021-12-08 Cadent Therapeutics Inc N-(4,4-difluorociclohexil)-2-(3-metil-1h-pirazol-1-il)-6-morfolinopirimidin-4-amina útil como modulador de canales de potasio
BR112020018601A2 (pt) 2018-03-14 2020-12-29 Janssen Sciences Ireland Unlimited Company Regime de dosagem de modulador de montagem de capsídeo
AU2019366312B2 (en) 2018-10-22 2025-04-24 Novartis Ag Crystalline forms of potassium channel modulators
AU2020223865A1 (en) 2019-02-22 2021-07-15 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
TW202108576A (zh) 2019-05-06 2021-03-01 愛爾蘭商健生科學愛爾蘭無限公司 用於治療hbv感染或hbv誘發的疾病之醯胺衍生物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL248308A (el) 1958-09-30
US4104385A (en) 1976-08-19 1978-08-01 Sterling Drug Inc. Cyclic alkylidenyl N-[6-(amino)-3-pyridazinyl]aminomethylenemalonates
AU2002220276A1 (en) 2000-12-12 2002-06-24 Neurogen Corporation Spiro(isobenzofuran-1,4'-piperidin)-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
FR2832148B1 (fr) * 2001-11-14 2004-05-21 Oreal Nouvelles bases d'oxydation 2,5-diaminopyridine utiles pour la teinture des fibres keratiniques
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
ATE359782T1 (de) 2003-01-16 2007-05-15 Sb Pharmco Inc Heteroaryl-substituierte pyrrol(2, 3- b)pyridin- derivate als crf-rezeptor-antagonisten
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
GB0314136D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0322016D0 (en) 2003-09-19 2003-10-22 Merck Sharp & Dohme New compounds
WO2005028452A1 (en) 2003-09-22 2005-03-31 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
WO2005035526A1 (en) 2003-10-09 2005-04-21 Argenta Discovery Ltd. Bicyclic compounds and their therapeutic use
GB0326633D0 (en) * 2003-11-14 2003-12-17 Merck Sharp & Dohme Therapeutic agents
EP1802603A1 (en) 2004-10-12 2007-07-04 AstraZeneca AB Quinoline derivatives
US7875627B2 (en) * 2004-12-07 2011-01-25 Abbott Laboratories Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
JP2009501217A (ja) 2005-07-15 2009-01-15 アストラゼネカ アクチボラグ 治療薬
EP1963313B1 (en) * 2005-11-28 2012-11-14 Madrigal Pharmaceuticals, Inc. Inhibitors of diacylglycerol acyltransferase (dgat)

Also Published As

Publication number Publication date
DE602007004119D1 (de) 2010-02-11
ZA200900505B (en) 2010-04-28
NO20090952L (no) 2009-04-23
CN101511819A (zh) 2009-08-19
FR2904316A1 (fr) 2008-02-01
EP2049525A1 (fr) 2009-04-22
UY30518A1 (es) 2008-02-29
MA30695B1 (fr) 2009-09-01
JO2644B1 (en) 2012-06-17
IL196571A0 (en) 2009-11-18
EP2049525B1 (fr) 2009-12-30
EA017375B1 (ru) 2012-12-28
CA2658799A1 (fr) 2008-02-07
ES2338610T3 (es) 2010-05-10
CO6150179A2 (es) 2010-04-20
ATE453637T1 (de) 2010-01-15
US7786104B2 (en) 2010-08-31
US20090156573A1 (en) 2009-06-18
WO2008015335A1 (fr) 2008-02-07
RS51235B (sr) 2010-12-31
ME00590A (en) 2011-12-20
SI2049525T1 (sl) 2010-04-30
MY145031A (en) 2011-12-15
TW200813023A (en) 2008-03-16
PT2049525E (pt) 2010-03-23
JP5306201B2 (ja) 2013-10-02
NZ574345A (en) 2011-11-25
KR20090033885A (ko) 2009-04-06
FR2904316B1 (fr) 2008-09-05
DK2049525T3 (da) 2010-05-03
CL2007002169A1 (es) 2008-03-07
CA2658799C (fr) 2014-10-07
PL2049525T3 (pl) 2010-07-30
EA200970171A1 (ru) 2009-06-30
AU2007280326B2 (en) 2012-11-29
US20100286119A1 (en) 2010-11-11
BRPI0715199A2 (pt) 2013-10-01
MX2009001222A (es) 2009-02-13
HRP20100121T1 (hr) 2010-04-30
CN101511819B (zh) 2014-04-23
US8586573B2 (en) 2013-11-19
AU2007280326A1 (en) 2008-02-07
AR062143A1 (es) 2008-10-15
PE20080688A1 (es) 2008-07-24
JP2009545574A (ja) 2009-12-24

Similar Documents

Publication Publication Date Title
CY1109944T1 (el) Παραγωγα ν-(αμινο-ετεροαρυλ)-1η-ινδολ-2-καρβοξαμιδιων, η παρασκευη τους και η εφαρμογη τους σε θεραπειες
CY1113470T1 (el) Παραγωγα ν-(αμινο-ετεροαρυλ)-1η-ινδολο-2-καρβοξαμιδιων ως ανταγωνιστες υποδοχεων τυπου trpv1 ή vr1
CY1124357T1 (el) Προσδιορισμος ανισορροπιας αλληλουχιας νουκλεϊκων οξεων
CY1121599T1 (el) Νεο παραγωγο αμινης ή αλας αυτου ως παρεμποδιστες tnf αλφα
CY1111294T1 (el) Συνθεση αμιδιων ακυλαμινοαλκενυλενιου χρησιμων ως ανταγωνιστων της ουσιας ρ
CY1111922T1 (el) 1-ετεροκυκλυλσουλφονυλ, 2-αμινομεθυλ, 5-(ετερο-)αρυλ υποκατεστημενα 1-η-πυρρολιου παραγωγα ως αναστολεις εκκρισης οξεος
EA201070873A1 (ru) Производные n-азабициклических карбоксамидов, их получение и применение в терапии
CY1122062T1 (el) Νεες συγχωνευμενες πυριδινικες ενωσεις ως αναστολεις κινασης της καζεϊνης
CY1108183T1 (el) Θειαζολυλο-διυδρο-ινδαζολια
JP2017071790A5 (el)
UY30050A1 (es) Derivados de pirimido-oxazinil-fenilo, sales de los mismos, composiciones, preparaciones y aplicaciones
CY1110419T1 (el) Τρικυκλικες ενωσεις με βαση το 1,6-διυδρο-1,3,5,6-tetpaaza-as-ινδακενιο και φαρμακευτικες συνθεσεις που τις περιεχουν ως αναστολεις της ενζυμικης ενεργοτητας της ικκ
CY1115199T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαϋμυκινης και η θεραπευτικη τους χρηση
CY1108267T1 (el) Ενωσεις που επηρεαζουν τη γλυκοκιναση
CY1112286T1 (el) Παραγωγα πυραζολιου χρησιμα για τη θεραπεια γυναικολογικων ασθενειων
BR112014010813A2 (pt) n-(tetrazol-5-il)-aril-carboxamidas e n-(triazol-5-il)-aril-carboxamidas substituídas em 5-fenilo e sua utilização como herbicidas
CY1112276T1 (el) Παραγωγα (3-αμινο-1,2,3,4-τετραϋδρο-9h-καρβαζολ-9-υλ)- οξικου οξεος
CY1112520T1 (el) Βενζυλαμινες, μια διαδικασια για την παραγωγη τους και η χρηση τους ως αντι-φλεγμονωδεις παραγοντες
CY1113266T1 (el) Παραγωγο αρυλαμιδινης, αλας αυτου και αντιμυκητιασικο περιεχον αυτα
CY1118173T1 (el) 5-[(3,3,3-τριφθορο-2-υδροξυ-1-αρυλπροπυλ)αμινο]-1h-κινολιν-2-ονες, μια διεργασια για την παραγωγη τους και η χρηση τους ως αντι-φλεγμονωδων παραγοντων
JP2015527363A5 (el)
MX377235B (es) Proceso mejorado para preparar bifenilanilidas y bifenilanilinas cloradas.
ATE482221T1 (de) Bisamid-zinkbasen
EA200971044A1 (ru) Арил- и гетероарилзамещенные тетрагидробензо-1,4-диазепины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
CY1121484T1 (el) Μορφες αλατος και κρυσταλλου ενος αναστολεα plk-4